News
-
ONL Therapeutics to Present at EYENOVATE and the FLORetina–ICOOR Congress 2025
-
ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD
-
ONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings
-
ONL Therapeutics Appoints Penny Fleck as Chief Development Officer
-
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
-
ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight
-
ONL Therapeutics To Present At 2024 BIO CEO & Investor Conference
-
ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society
-
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment